Market Cap 672.51M
Revenue (ttm) 263.40M
Net Income (ttm) -198.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -75.51%
Debt to Equity Ratio 0.00
Volume 3,459,500
Avg Vol 2,100,256
Day's Range N/A - N/A
Shares Out 73.42M
Stochastic %K 28%
Beta 2.39
Analysts Sell
Price Target $12.12

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders f...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 535 1456
Address:
5 Science Park, 395 Winchester Avenue, New Haven, United States
Thestocktraderhubzee
Thestocktraderhubzee Oct. 23 at 10:03 AM
WATCHLIST OCT 23 2025. $BURU Nuburu shares are trading higher after the company entered into a strategic framework agreement with Nuburu Defense and Maddox Defense to establish a joint venture company. $ARVN Arvinas To Present Preclinical Data For ARV-806 At 2025 At AACR-NCI-EORTC International Conference In Boston $HON Honeywell International Expects To Complete Separation Of Solstice Advanced Materials Business On Oct. 30, Aerospace Technologies Operations In H2 2026 $SLMT Solmate Infrastructure Provides Update On Its Validator Operations, Data Center Selection, M&A Strategy, And $300M Oversubscribed Pipe Financing And Plans To File The Registration Statement For Pipe Investor Shares By November 22, 2025 $GPUS Hyperscale Data Announces Intent To Launch On-Demand NVIDIA Graphics Processing Unit Cloud Platform From Michigan AI Data Center Campus
0 · Reply
TwongStocks
TwongStocks Oct. 22 at 8:04 PM
$ARVN Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics https://ir.arvinas.com/news-releases/news-release-details/arvinas-present-preclinical-data-arv-806-protac-kras-g12d
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 20 at 12:15 PM
$ARVN (-1.5% pre) Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy https://ooc.bz/l/81134
1 · Reply
buyandsold
buyandsold Oct. 17 at 11:21 PM
$ARVN NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that new data for vepdegestrant will be presented at the European Society for Medical Oncology (ESMO) Congress to be held October 17 through 21, 2025, in Berlin, Germany.
0 · Reply
buyandsold
buyandsold Oct. 17 at 11:18 PM
$ARVN monday's vepdeg presentation can hardly be expected to be of any consequence give that PFE knows the data and kicked it to the kerb
1 · Reply
JBSchulte
JBSchulte Oct. 16 at 5:54 PM
$ARVN so Goldman downgrades the stock to 6 and it pops above 10? Any theories as to why?
1 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 16 at 5:24 PM
$ARVN trimming a little
0 · Reply
TwongStocks
TwongStocks Oct. 15 at 9:30 PM
$ARVN Logos Global Management filed a new 13D this afternoon. https://www.sec.gov/Archives/edgar/data/1792126/000093583625000639/xslSCHEDULE_13D_X01/primary_doc.xml Reporting beneficial ownership of 2.5m shares, 3.4%. Under Item 5(e), they report that they ceased to be beneficial owners of 5% on Oct 13. As a result, they will no longer be required to make 13D filings until they go back over 5%. Exhibit 99.2 lists their sales over the past 60 days. https://www.sec.gov/Archives/edgar/data/1655759/000093583625000639/ex992.htm
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 11:25 AM
Goldman Sachs has adjusted their stance on Arvinas ( $ARVN ), setting the rating to Sell with a target price of 8 → 6.
3 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 13 at 7:28 PM
$ARVN nice little 225k print there
0 · Reply
Latest News on ARVN
Arvinas to Participate in Upcoming Investor Conferences

Aug 29, 2025, 7:00 AM EDT - 2 months ago

Arvinas to Participate in Upcoming Investor Conferences


Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 1:24 PM EDT - 2 months ago

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript


Arvinas to Present at Jefferies Global Healthcare Conference

May 30, 2025, 7:00 AM EDT - 5 months ago

Arvinas to Present at Jefferies Global Healthcare Conference


Thestocktraderhubzee
Thestocktraderhubzee Oct. 23 at 10:03 AM
WATCHLIST OCT 23 2025. $BURU Nuburu shares are trading higher after the company entered into a strategic framework agreement with Nuburu Defense and Maddox Defense to establish a joint venture company. $ARVN Arvinas To Present Preclinical Data For ARV-806 At 2025 At AACR-NCI-EORTC International Conference In Boston $HON Honeywell International Expects To Complete Separation Of Solstice Advanced Materials Business On Oct. 30, Aerospace Technologies Operations In H2 2026 $SLMT Solmate Infrastructure Provides Update On Its Validator Operations, Data Center Selection, M&A Strategy, And $300M Oversubscribed Pipe Financing And Plans To File The Registration Statement For Pipe Investor Shares By November 22, 2025 $GPUS Hyperscale Data Announces Intent To Launch On-Demand NVIDIA Graphics Processing Unit Cloud Platform From Michigan AI Data Center Campus
0 · Reply
TwongStocks
TwongStocks Oct. 22 at 8:04 PM
$ARVN Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics https://ir.arvinas.com/news-releases/news-release-details/arvinas-present-preclinical-data-arv-806-protac-kras-g12d
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 20 at 12:15 PM
$ARVN (-1.5% pre) Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy https://ooc.bz/l/81134
1 · Reply
buyandsold
buyandsold Oct. 17 at 11:21 PM
$ARVN NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that new data for vepdegestrant will be presented at the European Society for Medical Oncology (ESMO) Congress to be held October 17 through 21, 2025, in Berlin, Germany.
0 · Reply
buyandsold
buyandsold Oct. 17 at 11:18 PM
$ARVN monday's vepdeg presentation can hardly be expected to be of any consequence give that PFE knows the data and kicked it to the kerb
1 · Reply
JBSchulte
JBSchulte Oct. 16 at 5:54 PM
$ARVN so Goldman downgrades the stock to 6 and it pops above 10? Any theories as to why?
1 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 16 at 5:24 PM
$ARVN trimming a little
0 · Reply
TwongStocks
TwongStocks Oct. 15 at 9:30 PM
$ARVN Logos Global Management filed a new 13D this afternoon. https://www.sec.gov/Archives/edgar/data/1792126/000093583625000639/xslSCHEDULE_13D_X01/primary_doc.xml Reporting beneficial ownership of 2.5m shares, 3.4%. Under Item 5(e), they report that they ceased to be beneficial owners of 5% on Oct 13. As a result, they will no longer be required to make 13D filings until they go back over 5%. Exhibit 99.2 lists their sales over the past 60 days. https://www.sec.gov/Archives/edgar/data/1655759/000093583625000639/ex992.htm
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 11:25 AM
Goldman Sachs has adjusted their stance on Arvinas ( $ARVN ), setting the rating to Sell with a target price of 8 → 6.
3 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 13 at 7:28 PM
$ARVN nice little 225k print there
0 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 13 at 7:21 PM
$ARVN and best of all.. it's quiet here.
2 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 13 at 7:19 PM
$ARVN 94% institutional holding
0 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 13 at 7:18 PM
$ARVN 100m buy back ... 4 or 5 years of cash .. could cont up strong
0 · Reply
SaluteYourShorts
SaluteYourShorts Oct. 13 at 7:16 PM
$ARVN lighting up ... unusal opts
0 · Reply
biopuzzle
biopuzzle Oct. 13 at 7:12 PM
$ARVN My guess is the Big Boys are returning...
1 · Reply
biopuzzle
biopuzzle Oct. 13 at 3:26 PM
$ARVN a pennant is forming. I like it.
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 13 at 2:30 PM
$CCCC i've started a position here today and will add along the way. only a matter of time before the market realizes the opportunity here. my favorite tpd companies right now are $CCCC $GLUE $ARVN and $NRIX .
1 · Reply
georgenobest
georgenobest Oct. 11 at 6:42 PM
$ARVN CATX more than 300% upside. Catalyst coming next week. The move just started https://in.investing.com/news/analyst-ratings/btig-initiates-coverage-on-perspective-therapeutics-stock-with-buy-rating-93CH-5038968
0 · Reply
Social_Idiot
Social_Idiot Oct. 8 at 5:43 PM
$ARVN Best decision that I've made all year.
1 · Reply
buyandsold
buyandsold Oct. 7 at 12:57 AM
$ARVN well that was degrading Time to liquidate when nobody believes your encourgaing P1 data
1 · Reply
jjrrjjrr
jjrrjjrr Oct. 6 at 6:11 PM
1 · Reply
outlawinvestor1
outlawinvestor1 Oct. 6 at 3:23 PM
$ARVN @MOTP perhaps resistance at $11/12 due to drop to ~$6 after vepdeg ph3 readout combined with continued investor caution. despite my own negative feelings about management, i believe it's a buy at current levels and this is a gift. despite vepdeg upset, it's still an active drug that will be used after approval. on top of that, they have 3 shots on goal in the clinic now (arvn102 (lrrk2), arvn393 (bcl6), and arvn?? (krasg12d) + an oral protac platform that has been validated in onc with vepdeg (and now partially in neuro). this stock is still trading below cash, thus the market is ascribing negative value to a company that has all of the above. if they were to be acquired today, i would imagine that they could command any where from $4-8 billion without doing the math.
1 · Reply